| Literature DB >> 32440236 |
Marwa Yahia Mahgoub1, Basant Mohamed Elnady1, Haytham Sayed Abdelkader2, Raghdaa Abdelkhaleq Abdelhalem2, Waleed Ahmed Hassan1.
Abstract
BACKGROUND: Knee osteoarthritis (OA) is a painful condition with peripheral and central pain transmission. Fibromyalgia (FM) is the role model of central sensitization of pain perception. AIM: To assess the frequency of FM in knee OA patients and evaluate the impact of FM on mental health and the quality of life in knee OA patients. PATIENTS AND METHODS: A total of 121 female patients were recruited and divided into 3 groups: group I of 59 patients with knee OA only, group II of 32 patients with knee OA and FM, and group III of 30 FM patients. Patients underwent history taking, examination, investigations, and radiological evaluation of both knees. The assessment of visual analog scale (VAS), Pittsburgh Sleep Quality Index (PSQI), Pain Anxiety Symptom Scale Short Form 20 (PASS20), Beck Depression Inventory (BDI-II), and PCASEE questionnaire were done for all patients. Lequesne index of knee OA and radiological Kellgren and Lawrence score severity were done for all OA patients. Fibromyalgia Impact Questionnaire (FIQ) was assessed for all FM patients.Entities:
Keywords: central sensitization; fibromyalgia; knee osteoarthritis; osteoarthritis pain
Year: 2020 PMID: 32440236 PMCID: PMC7212986 DOI: 10.2147/OARRR.S252748
Source DB: PubMed Journal: Open Access Rheumatol ISSN: 1179-156X
Baseline Characteristics of Different Groups
| Variable | KOA (n=59) Group I | KOA Patients with FM (n=32) Group II | FM (n=30) Group III | P value | ||
|---|---|---|---|---|---|---|
| Demographic | Age (years) | Mean ± SD | 53.4 ± 7.2 | 37.5 ± 6.9 | 47.3 ± 4.6 | < 0.001* |
| BMI | Mean ± SD | 33.4 ± 3.1 | 29.5 ± 3.9 | 33.3 ± 3.4 | < 0.001* | |
| Residence | (Rural: Urban) | (34:25) | (18:12) | (22:10) | 0.58 | |
| Marital status | (Married: not married) | (49:10) | (19:11) | (23:9) | 0.11 | |
| Educational level | (Literate: Illiterate) | (39:20) | (26:4) | (26:6) | 0.07 | |
| Clinical | Disease duration (years) | Median (IQR) | 3 (2–5) | 2(2–3) | 2 (1–3.5) | 0.07 |
| KL grades | I n(%) | 16(27.1%) | —– | 18 (56.3%) | 0.02* | |
| II n(%) | 17(28.8%) | —– | 7(21.9%) | |||
| III n(%) | 26 (44.1%) | —– | 7(21.9%) | |||
| VAS | Median (IQR) | 3 (2.0−4.75) | 5 (3−7) | 6 (5–8) | < 0.001* | |
| PSQI | Mean ± SD | 7.5± 1.7 | 9.1± 2.7 | 12.5± 2.5 | < 0.001* | |
| PASS20 | Mean ± SD | 35.9± 8.4 | 40.5± 8.6 | 47.8± 10.9 | <0.001* | |
| BDI-II | Median (IQR) | 5 (2–7) | 22.5(18–27) | 14(9–17.5) | <0.001* | |
| Lequesene score | Median (IQR) | 5(4–7) | —– | 7(5.5–12) | <0.001* | |
| FIQ | Mean ± SD | —– | 42.8 ± 13.2 | 49.5± 20.7 | 0.14 | |
| Quality of life | Physical | Mean± SD | 49.8 ±14.7 | 62.1± 14.4 | 47.6 ±14.1 | <0.001* |
| Cognitive | Mean± SD | 55.6± 15 | 51.3± 14.8 | 49.9± 16.6 | 0.2 | |
| Affective | Mean± SD | 53.5± 14.3 | 47.6 ± 15.1 | 34.4± 17.3 | < 0.001* | |
| Social | Mean± SD | 50.5 ± 15.2 | 55.2 ± 12.4 | 45.8 ± 13.8 | 0.04* | |
| Economic | Mean± SD | 55.2± 19.1 | 60.9± 16.5 | 54.8± 22.5 | 0.36 | |
| Ego | Mean± SD | 47.8 ± 16 | 35.9± 14.9 | 34.9± 15.9 | < 0.001* | |
| Medications | Acetaminophen | n (%) | 49(83%) | 15 (50%) | 20 (62.5%) | 0.004* |
| NSAIDS | n (%) | 46 (78%) | 22 (73.3%) | 27(84.4%) | 0.6 | |
| Antidepressant | n (%) | 4(6.8%) | 27(90%) | 12(37.5%) | <0.001* | |
| Gabapentinoids | n (%) | 9(15.3%) | 24(80%) | 16(50%) | <0.001* | |
| Chondroprotectives | n (%) | 46(78%) | 0(0%) | 21(65.6%) | 0.3 | |
Notes: P1: between KOA group and FM group; p2: between FM group and KOA patients with FM co-morbidity group; p3: between KOA group and KOA patients with FM co-morbidity group. *p<0.05.
Abbreviations: KOA, knee osteoarthritis; FM, fibromyalgia; BMI, body mass index; KL, Kellgren and Lawrence; VAS, visual analog scale; PSQI, Pittsburgh Sleep Quality Index; PASS20, Pain Anxiety Symptom Scale Short Form 20; BDI-II, Beck Depression Inventory; FIQ, Fibromyalgia Impact Questionnaire; NSAIDS, non-steroidal anti-inflammatory drugs.
Figure 1Quality of life in different groups.
Note: *P<0.05.
Abbreviations: KOA, knee osteoarthritis; FM, fibromyalgia.
Correlation of Different Parameters in KOA Patients with FM Comorbidity
| Parameters | VAS | PASS20 | BDI-II | Lequesne | |||||
|---|---|---|---|---|---|---|---|---|---|
| p | p | p | p | ||||||
| Age | 0.17 | 0.35 | 0.46 | 0.009* | 0.13 | 0.49 | 0.2 | 0.27 | |
| BMI | 0.53 | 0.002* | 0.04 | 0.84 | 0.29 | 0.11 | 0.38 | 0.03* | |
| Disease duration | 0.04 | 0.84 | 0.16 | 0.37 | 0.09 | 0.64 | 0.2 | 0.26 | |
| VAS | —– | —– | 0.48 | 0.006* | 0.53 | 0.002* | 0.64 | <0.001* | |
| PSQI | 0.23 | 0.21 | 0.4 | 0.02* | 0.18 | 0.32 | 0.28 | 0.11 | |
| PASS20 | 0.48 | 0.006* | —– | —– | 0.25 | 0.16 | 0.37 | 0.04* | |
| BDI-II | 0.53 | 0.002* | 0.25 | 0.16 | —– | —– | 0.17 | 0.37 | |
| Lequesne’s score | 0.64 | <0.001* | 0.37 | 0.04* | 0.17 | 0.37 | —– | —– | |
| FIQ | 0.56 | <0.001* | 0.77 | <0.001* | 0.32 | 0.07 | 0.47 | 0.006* | |
| Quality of life | Physical | −0.62 | <0.001* | −0.71 | <0.001* | −0.4 | 0.02* | −0.42 | 0.02* |
| Cognitive | −0.1 | 0.57 | −0.47 | 0.007* | 0.1 | 0.6 | −0.09 | 0.6 | |
| Affective | −0.36 | 0.046* | −0.67 | <0.001* | −0.1 | 0.6 | −0.32 | 0.08 | |
| Social | −0.39 | 0.026* | −0.7 | <0.001* | −0.35 | 0.049* | −0.29 | 0.1 | |
| Economic | 0.12 | 0.52 | −0.11 | 0.56 | −0.03 | 0.87 | −0.04 | 0.85 | |
| Ego | −0.03 | 0.88 | −0.5 | 0.004* | 0.13 | 0.49 | −0.04 | 0.85 | |
Note: *p<0.05.
Abbreviations: KOA, knee osteoarthritis; FM, fibromyalgia; BMI, body mass index; VAS, visual analog scale; PSQI, Pittsburgh Sleep Quality Index; PASS20, Pain Anxiety Symptom Scale Short Form 20; BDI-II, Beck Depression Inventory; FIQ, Fibromyalgia Impact Questionnaire.
Correlation of Different Parameters in Confined KOA Group
| Parameters | VAS | PASS20 | BDI-II | Lequesne | |||||
|---|---|---|---|---|---|---|---|---|---|
| p | p | P | p | ||||||
| Age | 0.07 | 0.61 | −0.2 | 0.13 | −0.06 | 0.63 | 0.07 | 0.59 | |
| BMI | 0.3 | 0.03* | 0.03 | 0.84 | 0.36 | 0.005* | 0.3 | 0.03* | |
| Disease duration | 0.05 | 0.7 | 0.21 | 0.1 | 0.15 | 0.26 | 0.14 | 0.3 | |
| VAS | —– | —– | 0.05 | 0.71 | 0.11 | 0.39 | 0.74 | <0.001* | |
| PSQI | 0.05 | 0.73 | 0.38 | 0.003* | 0.33 | 0.01* | 004 | 0.74 | |
| PASS20 | 0.05 | 0.71 | —– | —– | 0.27 | 0.04* | 0.22 | 0.09 | |
| BDI-II | 0.11 | 0.39 | 0.27 | 0.04* | —– | —– | 0.02 | 0.85 | |
| Lequesne’s score | 0.74 | <0.001* | 0.22 | 0.09 | 0.02 | 0.85 | —– | —– | |
| Quality of life | Physical | −0.54 | <0.001* | −0.31 | 0.02* | 0.06 | 0.67 | −0.65 | <0.001* |
| Cognitive | −0.09 | 0.52 | −0.03 | 0.82 | 0.13 | 0.34 | −0.19 | 0.15 | |
| Affective | −0.12 | 0.37 | −0.39 | 0.002* | −0.23 | 0.08 | −0.14 | 0.3 | |
| Social | −0.55 | <0.001* | −0.34 | 0.009* | 0.1 | 0.42 | −0.6 | <0.001* | |
| Economic | 0.05 | 0.73 | −0.16 | 0.23 | −0.07 | 0.58 | 0.15 | 0.24 | |
| Ego | −0.18 | 0.17 | −0.25 | 0.06 | −0.16 | 0.24 | −0.3 | 0.02* | |
Note: *p<0.05.
Abbreviations: KOA, knee osteoarthritis; BMI,body mass index; VAS, visual analog scale; PSQI, Pittsburgh Sleep Quality Index; PASS20, Pain Anxiety Symptom Scale Short Form 20; BDI-II, Beck Depression Inventory.
Linear Regression Analysis for Prediction of Factors Affecting Quality of Life in All Studied KOA Patients
| Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
| P value | β | P value | β | |
| Age | 0.484744 | 1.2234 | ||
| BMI | 0.239142 | 0.11234 | ||
| Disease duration | 0.232511 | 0.3456 | ||
| Lequesne’s score | 0.049234* | 0.11381 | 3.3787 | −1.2828 |
| VAS | 0.96678 | −2.157 | ||
| PSQI | 0.000272* | −1.289 | 0.0334* | −1.08364 |
| PASS20 | 0.103467 | −0.6000 | ||
| BDI-II | 0.012142* | −0.4292 | 0.8613 | −0.034 |
| FM | 0.00319* | −6.886 | 0.05793 | 1.86320 |
Notes: *p<0.05. β: regression coefficient.
Abbreviations: KOA, knee osteoarthritis; FM, fibromyalgia; BMI, body mass index; VAS, visual analog scale; PSQI, Pittsburgh Sleep Quality Index; PASS20, Pain Anxiety Symptom Scale Short Form 20; BDI-II, Beck Depression Inventory.
Linear Regression Analysis for Prediction of Factors Affecting Lequesene’s Score in All Studied KOA Patients
| Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
| P value | β | P value | β | |
| Age | 0.60895 | −0.027146 | ||
| BMI | 0.003511* | 0.33460 | 0.046788105* | 0.1720 |
| Disease duration | 0.57293 | 0.1060 | ||
| VAS | 0.36687 | 1.0920 | ||
| PQAI | 0.008671* | 0.3093 | 0.664619446 | −0.0558 |
| PASS 20 | 0.60 | 0.13076 | ||
| BDI-II | 0.014601* | 0.1368 | 0.012639246* | −0.13515 |
| FM | 0.000828* | 2.5132 | 0.298019997 | 0.957599 |
Notes: *p<0.05. β: regression coefficient.
Abbreviations: KOA, knee osteoarthritis; FM, fibromyalgia; BMI, body mass index; VAS, visual analog scale; PSQI, Pittsburgh Sleep Quality Index; PASS20, Pain Anxiety Symptom Scale Short Form 20; BDI-II, Beck Depression Inventory.
Linear Regression Analysis for Prediction of Factors Affecting Quality of Life in Combined KOA and FM Patients
| Univariable | Multivariable | |||
|---|---|---|---|---|
| β | p | β | p | |
| Age | −1.020 | 0.023* | −0.100 | 0.773 |
| BMI | −0.182 | 0.774 | ||
| Disease duration | −2.052 | 0.112 | ||
| Lequesene’s score | −1.078 | 0.074 | ||
| VAS | −2.251 | 0.046* | −0.222 | 0.810 |
| PSQI | −1.762 | 0.034* | −0.581 | 0.379 |
| PASS20 | −0.382 | <0.001* | −0.944 | <0.001* |
| FIQ | −0.298 | 0.002* | −0.138 | 0.260 |
| BDI-II | −0.317 | 0.363 | ||
Notes: *p<0.05. β: regression coefficient.
Abbreviations: KOA, knee osteoarthritis; FM, fibromyalgia; BMI, body mass index; VAS, visual analog scale; PSQI, Pittsburgh Sleep Quality Index; PASS20, Pain Anxiety Symptom Scale Short Form 20; FIQ, Fibromyalgia Impact Questionnaire; BDI-II, Beck Depression Inventory.